Literature DB >> 25142823

Effect of arginine on pre-nucleus stage of interferon beta-1b aggregation.

Ahmad Fazeli1, Mohadeseh Haji-Abdolvahab, Seyed Abbas Shojaosadati, Huub Schellekens, Khosro Khalifeh, Ali Akbar Moosavi-Movahedi, Mohammad Reza Fazeli.   

Abstract

Understanding the mechanism of aggregation of a therapeutic protein would not only ease the manufacturing processing but could also lead to a more stable finished product. Aggregation of recombinant interferon (IFNβ-1b) was studied by heating, oxidizing, or seeding of unformulated monomeric solution. The formation of aggregates was monitored by dynamic light scattering (DLS) and UV spectroscopy. The autocatalytic monomer loss model was used to fit the data on aggregation rates. The influence of pre-nucleation on aggregation step was demonstrated by inducing the liquid samples containing a monomer form of folded IFNβ-1b by heat and also an oxidizing agent. Results tend to suggest that the nucleus includes a single protein molecule which has been probably deformed. Seeding tests showed that aggregation of IFNβ-1b was probably initiated when 1.0% (w/w) of monomers converted to nucleus form. Chemiluminescence spectroscopy analysis of the sample indicated the generation of 3.0 μM of hydrogen peroxide (H2O2) during nucleation stage of IFNβ-1b aggregation. Arginine with a concentration of 200 mM was sufficient to suppress aggregation of IFNβ-1b by decreasing the rate of pre-nucleation step. We proposed the formation of pre-nucleus structures prior to nucleation as the mechanism of aggregation of IFNβ-1b. Furthermore, we have showed the positive anti-aggregation effect of arginine on pre-nucleation step.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25142823      PMCID: PMC4245421          DOI: 10.1208/s12249-014-0192-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  28 in total

Review 1.  Quantification and significance of protein oxidation in biological samples.

Authors:  E Shacter
Journal:  Drug Metab Rev       Date:  2000 Aug-Nov       Impact factor: 4.518

2.  Interaction of arginine with proteins and the mechanism by which it inhibits aggregation.

Authors:  Diwakar Shukla; Bernhardt L Trout
Journal:  J Phys Chem B       Date:  2010-10-28       Impact factor: 2.991

Review 3.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

4.  Rational design of solution additives for the prevention of protein aggregation.

Authors:  Brian M Baynes; Bernhardt L Trout
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

Review 5.  Role of arginine in protein refolding, solubilization, and purification.

Authors:  Kouhei Tsumoto; Mitsuo Umetsu; Izumi Kumagai; Daisuke Ejima; John S Philo; Tsutomu Arakawa
Journal:  Biotechnol Prog       Date:  2004 Sep-Oct

6.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

7.  Facilitated protein aggregation. Effects of calcium on the chaperone and anti-chaperone activity of protein disulfide-isomerase.

Authors:  T P Primm; K W Walker; H F Gilbert
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

8.  Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

Authors:  James G Barnard; Ken Babcock; John F Carpenter
Journal:  J Pharm Sci       Date:  2012-12-11       Impact factor: 3.534

9.  Development of a transgenic mouse model immune tolerant for human interferon Beta.

Authors:  Suzanne Hermeling; Wim Jiskoot; Daan Crommelin; Claus Bornaes; Huub Schellekens
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

10.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.

Authors:  Songming Chen; Frank A Ferrone; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

View more
  1 in total

1.  Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation.

Authors:  Najmeh Mahjoubi; Mohammad Reza Fazeli; Rassoul Dinarvand; Mohammad Reza Khoshayand; Ahmad Fazeli; Mohammad Taghavian; Hossein Rastegar
Journal:  Adv Pharm Bull       Date:  2015-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.